BioXcel Therapeutics is the subject of a $9,750,000 class action settlement covering investors who purchased or acquired BioXcel Therapeutics common stock between March 9, 2023, and June 28, 2023. The lawsuit alleged securities law violations during that period, and eligible shareholders may receive approximately $1.52 per share before deductions. A verified claim deadline of June 30, 2026 applies, and proof of purchase is required to file through the official claim form.